|
1
|
Japan Esophageal Society, . Comprehensive
Registry of Esophageal Cancer in Japan. 3rd. 2002 1–May.
2009http://esophagus.jp
|
|
2
|
Muto M, Horimatsu T, Ezoe Y, Morita S and
Miyamoto S: Improving visualization techniques by narrow band
imaging and magnification endoscopy. J Gastroenterol Hepatol.
24:1333–1346. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhang XM and Guo MZ: The value of
epigenetic markers in esophageal cancer. Front Med China.
4:378–384. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ahrens TD, Werner M and Lassmann S:
Epigenetics in esophageal cancers. Cell Tissue Res. 356:643–655.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao H, Wang LD, Zhou Q, Hong JY, Huang TY
and Yang CS: p53 Tumor suppressor gene mutation in early esophageal
precancerous lesions and carcinoma among high-risk populations in
Henan. Cancer Res. 54:4342–4346. 1994.PubMed/NCBI
|
|
6
|
Montesano R, Hollstein M and Hainaut P:
Genetic alterations in esophageal cancer and their relevance to
etiology and pathogenesis: A review. Int J Cancer. 69:225–235.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Abedi-Ardekani B, Dar NA, Mir MM, Zargar
SA, Lone MM, Martel-Planche G, Villar S, Mounawar M, Saidi F,
Malekzadeh R and Hainaut P: Epidermal growth factor receptor (EGFR)
mutations and expression in squamous cell carcinoma of the
esophagus in central Asia. BMC Cancer. 12:6022012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mori R, Ishiguro H, Kimura M, Mitsui A,
Sasaki H, Tomoda K, Mori Y, Ogawa R, Katada T, Kawano O, et al:
PIK3CA mutation status in Japanese esophageal squamous cell
carcinoma. J Surg Res. 145:320–326. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ushijima T: Detection and interpretation
of altered methylation patterns in cancer cells. Nat Rev Cancer.
5:223–231. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kalari S and Pfeifer GP: Identification of
driver and passenger DNA methylation in cancer by epigenomic
analysis. Adv Genet. 70:277–308. 2010.PubMed/NCBI
|
|
11
|
Sato F and Meltzer SJ: CpG island
hypermethylation in progression of esophageal and gastric cancer.
Cancer. 106:483–493. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Mandelker DL, Yamashita K, Tokumaru Y,
Mimori K, Howard DL, Tanaka Y, Carvalho AL, Jiang WW, Park HL, Kim
MS, et al: PGP9.5 promoter methylation is an independent prognostic
factor for esophageal squamous cell carcinoma. Cancer Res.
65:4963–4968. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tzao C, Hsu HS, Sun GH, Lai HL, Wang YC,
Tung HJ, Yu CP, Cheng YL and Lee SC: Promoter methylation of the
hMLH1 gene and protein expression of human mutL homolog 1 and human
mutS homolog 2 in resected esophageal squamous cell carcinoma. J
Thorac Cardiovasc Surg. 130:13712005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang GY, Ma CX, Liu QL, Le XP, Ding Y and
Zhang QX: Detection of methylation of hMSH2 gene promoter region of
esophageal cancer. Zhonghua Zhong Liu Za Zhi. 27:541–543. 2005.(In
Chinese). PubMed/NCBI
|
|
15
|
Lee EJ, Lee BB, Kim JW, Shim YM, Hoseok I,
Han J, Cho EY, Park J and Kim DH: Aberrant methylation of fragile
histidine triad gene is associated with poor prognosis in early
stage esophageal squamous cell carcinoma. Eur J Cancer. 42:972–980.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee EJ, Lee BB, Han J, Cho EY, Shim YM,
Park J and Kim DH: CpG island hypermethylation of E-cadherin (CDH1)
and integrin alpha4 is associated with recurrence of early stage
esophageal squamous cell carcinoma. Int J Cancer. 123:2073–2079.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ling ZQ, Li P, Ge MH, Hu FJ, Fang XH, Dong
ZM and Mao WM: Aberrant methylation of different DNA repair genes
demonstrates distinct prognostic value for esophageal cancer. Dig
Dis Sci. 56:2992–3004. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Enzinger PC and Mayer RJ: Esophageal
cancer. N Engl J Med. 349:2241–2252. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Oze I, Matsuo K, Wakai K, Nagata C, Mizoue
T, Tanaka K, Tsuji I, Sasazuki S, Inoue M and Tsugane S; Research
Group for the Development and Evaluation of Cancer Prevention
Strategies in Japan, : Alcohol drinking and esophageal cancer risk:
An evaluation based on a systematic review of epidemiologic
evidence among the Japanese population. Jpn J Clin Oncol.
41:677–992. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Varela-Rey M, Woodhoo A, Martinez-Chantar
ML, Mato JM and Lu SC: Alcohol, DNA methylation, and cancer.
Alcohol Res. 35:25–35. 2013.PubMed/NCBI
|
|
21
|
Talukdar FR, Ghosh SK, Laskar RS and
Mondal R: Epigenetic, genetic and environmental interactions in
esophageal squamous cell carcinoma from northeast India. PLoS One.
8:e609962013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Portela A and Esteller M: Epigenetic
modifications and human disease. Nat Biotechnol. 28:1057–1068.
2010. View
Article : Google Scholar : PubMed/NCBI
|
|
23
|
Meng XY, Zhu ST, Zhou QZ, Li P, Wang YJ
and Zhang ST: Promoter methylation regulates cigarette
smoke-stimulated cyclooxygenase-2 expression in esophageal squamous
cell carcinoma. J Dig Dis. 13:208–213. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Gabbert HE, Shimoda T, Hainaut P, Nakamura
Y, Field JK and Inoue H: Squamous cell carcinoma of the
oesophagusHamilton SR and Aaltonen LA: World Health Organization
Classification of Tumours. Pathology and Genetics. Tumours of the
Digestive System Lyon: IARC Press; pp. 8–19. 2000
|
|
25
|
Kitamura A, Yashima K, Okamoto E, Andachi
H, Hosoda A, Kishimoto Y, Shiota G, Ito H, Kaibara N and Kawasaki
H: Reduced Fhit expression occurs in the early stage of esophageal
tumorigenesis: No correlation with p53 expression and apoptosis.
Oncology. 61:205–211. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baba Y, Watanabe M and Baba H: Review of
the alterations in DNA methylation in esophageal squamous cell
carcinoma. Surg Today. 43:1355–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Esteller M: CpG island hypermethylation
and tumor suppressor genes: A booming present, a brighter future.
Oncogene. 21:5427–5440. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Uehara H, Miyamoto M, Kato K, Cho Y,
Kurokawa T, Murakami S, Fukunaga A, Ebihara Y, Kaneko H, Hashimoto
H, et al: Deficiency of hMLH1 and hMSH2 expression is a poor
prognostic factor in esophageal squamous cell carcinoma. J Surg
Oncol. 92:109–115. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hayashi A, Yashima K..Takeda Y, Sasaki S,
Kawaguchi K, Harada K, Murawaki Y and Ito H: Fhit, E-cadherin, p53,
and activation-induced cytidine deaminase expression in
endoscopically resected early stage esophageal squamous neoplasia.
J Gastroenterol Hepatol. 27:1752–1758. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ishii T, Murakami J, Notohara K, Cullings
HM, Sasamoto H, Kambara T, Shirakawa Y, Naomoto Y, Ouchida M,
Shimizu K, et al: Oesophageal squamous cell carcinoma may develop
within a background of accumulating DNA methylation in normal and
dysplastic mucosa. Gut. 56:13–19. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jiricny J: Replication errors: Challenging
the genome. EMBO J. 17:6427–6436. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang J, Sasco AJ, Fu C, Xue H, Guo G, Hua
Z, Zhou Q, Jiang Q and Xu B: Aberrant DNA methylation of P16, MGMT,
and hMLH1 genes in combination with MTHFR C677T genetic
polymorphism in esophageal squamous cell carcinoma. Cancer
Epidemiol Biomarkers Prev. 17:118–125. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Konturek PC, Kania J, Burnat G, Hahn EG
and Konturek SJ: Prostaglandins as mediators of COX-2 derived
carcinogenesis in gastrointestinal tract. J Physiol Pharmacol. 56
Suppl 5:S57–S73. 2005.
|
|
34
|
Toyota M, Shen L, Ohe-Toyota M, Hamilton
SR, Sinicrope FA and Issa JP: Aberrant methylation of the
cyclooxygenase 2 CpG island in colorectal tumors. Cancer Res.
60:4044–4048. 2000.PubMed/NCBI
|
|
35
|
Huang L, Zhang KL, Li H, Chen XY, Kong QY,
Sun Y, Gao X, Guan HW and Liu J: Infrequent COX-2 expression due to
promoter hypermethylation in gastric cancers in Dalian, China. Hum
Pathol. 37:1557–1567. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Meng XY, Zhu ST, Zong Y, Wang YJ, Li P and
Zhang ST: Promoter hypermethylation of cyclooxy-genase-2 gene in
esophageal squamous cell carcinoma. Dis Esophagus. 24:444–449.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Mani S, Szymańska K, Cuenin C, Zaridze D,
Balassiano K, Lima SC, Matos E, Daudt A, Koifman S, Filho VW, et
al: DNA methylation changes associated with risk factors in tumors
of the upper aerodigestive tract. Epigenetics. 7:270–277. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lin RK, Hsieh YS, Lin P, Hsu HS, Chen CY,
Tang YA, Lee CF and Wang YC: The tobacco-specific carcinogen NNK
induces DNA methyltransferase 1 accumulation and tumor suppressor
gene hypermethylation in mice and lung cancer patients. J Clin
Invest. 120:521–532. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mori M, Mimori K, Shiraishi T, Alder H,
Inoue H, Tanaka Y, Sugimachi K, Huebner K and Croce CM: Altered
expression of Fhit in carcinoma precarcinomatous lesions of the
esophagus. Cancer Res. 60:1177–1182. 2000.PubMed/NCBI
|
|
40
|
Hasegawa M, Nelson HH, Peters E, Ringstrom
E, Posner M and Kelsey KT: Patterns of gene promoter methylation in
squamous cell cancer of the head and neck. Oncogene. 21:4231–4236.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Morita M, Oyama T, Nakata S, Ono K, Sugaya
M, Uramoto H, Yoshimatsu T, Hanagiri T, Sugio K and Yasumoto K:
Expression of fhit in esophageal epithelium and Carcinoma:
Reference to drinking, smoking and multicentric carcinogenesis.
Anticancer Res. 26:2243–2248. 2006.PubMed/NCBI
|
|
42
|
van Engeland M, Weijenberg MP, Roemen GM,
Brink M, De Bruïne AP, Goldbohm RA, van den Brandt PA, Baylin SB,
de Goeij AF and Herman JG: Effects of dietary folate and alcohol
intake on promoter methylation in sporadic colorectal cancer: The
Netherlands cohort study on diet and cancer. Cancer Res.
63:3133–3137. 2003.PubMed/NCBI
|
|
43
|
Ushijima T and Okochi-Takada E: Aberrant
methylations in cancer cells: Where do they come from? Cancer Sci.
96:206–211. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hollestein M, Sidransky D, Vogelstein B
and Harris CC: p53 mutations in human cancers. Science. 253:49–53.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Toh Y, Oki E, Ohgaki K, Sakamoto Y, Ito S,
Egashira A, Saeki H, Kakeji Y, Morita M, Sakaguchi Y, et al:
Alcohol drinking, cigarette smoking, and development of squamous
cell carcinoma of the esophagus: Molecular mechanisms of
carcinogenesis. Int J Clin Oncol. 15:135–144. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Kaneko K, Katagiri A, Konishi K, Kurahashi
T, Ito H, Kumekawa Y, Yamamoto T, Muramoto T, Kubota Y, Nozawa H,
et al: Study of p53 gene alteration as a biomarker to evaluate the
malignant risk of Lugol-unstained lesion with non-dysplasia in the
oesophagus. Br J Cancer. 96:492–498. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Chino O, Kijima H, Shimada H, Nishi T,
Tanaka H, Kise Y, Kenmochi T, Himeno S, Machimura T, Tanaka M, et
al: Accumulation of p53 in esophageal squamous cell carcinoma. Int
J Mol Med. 8:359–163. 2001.PubMed/NCBI
|
|
48
|
Perez-Ordoñez B, Beauchemin M and Jordan
RC: Molecular biology of squamous cell carcinoma of the head and
neck. J Clin Pathol. 59:445–453. 2006. View Article : Google Scholar : PubMed/NCBI
|
